Tag: mRNA cancer vaccine

4 predictions tagged with "mRNA cancer vaccine".

Personalized MRNA Cancer Vaccines Are Expected To Show Promising Phase 3 Trial Results.
Moderna And Merck's Personalized MRNA Neoantigen Cancer Vaccine Intismeran Autogene (V940/mRNA-4157) Is Expected To Receive Its First Regulatory Approval In 2028 As Adjuvant Treatment For High-risk Melanoma.
The Personalized MRNA Cancer Vaccine From Moderna And Merck (Intismeran Combined With Keytruda) Will Receive Its First Approval From A Major Regulator (FDA Or EMA).
Personalized MRNA Cancer Vaccines Will Gain Approval Or Enter Standard Adjuvant Care In At Least Two Cancer Types Beyond Melanoma (Lung And Pancreatic).